Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Glad to hear "cmz" I also was able to navigate through the 2014 R/S and am well up at this point, sorry you had to go through both.
The future is bright for those willing to endure.
Good Luck.
BLU
tmeier: 1/100 in 2014 which was the restructuring, and I believe that there was another around 2009 and another prior to that , cant find specifics at this moment.
The 1/100 was a success [I lived through it LOL]
If with all the news/catalysts moving forward hopefully price appreciation will continue on it's own, the markets perceive R/S's as a sign of weakness and lack of confidence by the company.
If we were not on OTC the pending news/catalyst [3/6/9 months moving forward would without question move stock to major exchange levels.
It seems that the science is so compelling I would think that institutions will not wish to miss out, and if Dart is not a seller float will be very, very tight and stock should appreciate in kind.
I am at a loss to find less than a handful of Bio tech stock in past years with two Phase 11 trials up and running that have not at some time within 5 years, with compelling science trading between $3/5.
Only time will tell hopefully the plan by management is to implement a game plan with our institutional holders to refrain from selling into their news.
In the next 6 months the forthcoming news should be more than sufficient to garner $3/5.
Believe that "another" R/S should be the very last resort to get up-listed.
Company is very solid at this point patience and news will prevail in the longer term.
Hope that helps.
BLU
Actually they have used the term "robust" on numerous occasions in the past year...but that "adjective' cannot be used enough in terms of how our science works.
90% + patients treated :}
I do however like the fact that they are incorporating the "noun" metastatic in most press.
GLTA
BLU
Hey tp: Are you sure about Fridays release? That would be great, meaning they are ahead of schedule on previous filings, that is a positive.
As to whether or not they will CC afterward, sorry but don't have an answer, if there are enough new factors in play, then they may to give more color and clarity.
I am hoping that they have some significant news [Dates] etc moving forward, BP partner at the top of my list, also would like to see they are moving forward with Polystart as it really strengthens the science. Although they have mentioned that may not happen till 2nd Q of 2016.
We are each day closer to getting news that should elevate the SP more towards $1 mark, would be great to see that [1/2 range] by year end. $1 plus will bolster our cash position.
The news that we need is BP partner, which should include milestones, and recurrence stats foremost I believe.
OTC seems to be a burden on us at this point, as no news seems to be able to spark enough buyers/holders of stock. Last thing I want is R/S if by mid 2016 [2Q] we are not $2 plus after initiating 2 trials then I would expect R/S. BP news should be monumental validation for the company.
For we have seen fantastic data, 13 mill in funding, and news of 2 trials and still stock will not break out...what is it going to take?
Either way we will all be winners long term with this investment, all the catalysts in play "should" make us compared to others listed on a major exchange [min $3/5] but alas we lie where many fear to tread.
I am not too familiar with investing in OTC stocks, but if we were on a major exchange we would not be under $1, I hope they do not finalize the BP agreement before they get approval from FDA on Orphan and or FT and or both trials up and running. But unfortunately for us that puts us into mid 2016.
The more time they wait the stronger negotiating position they will be in, I am glad that we have John to monitor those negotiations as I would have limited faith in Glynn.
We will all have more to talk about Friday then, need them to have moved forward on a few fronts.
Sorry at this point have no clue what it is going to take to really break us out at this point in time, but we must be very close...once again looks like 3 min/6 months till the company will be truly validated.
Float is tight, I'm not relinquishing a share, believe that many are now aware of our/their science and there is very little if anything negative at this point that can hold the stock down.
Other than the curse of the OTC.
GLTA
BLU
Some good size blocks changing hands.
Reminder: Tapimmune usually releases their Quarters, 6 weeks after quarter actually ends, late buying may have been a precursor of news.
This is end of Oct, their pattern shows that we should see Q3 release around Nov 14. Think that there should be some good color as to where they are in regards to Orphan, Fast track, partner etc.
GLTA
BLU
And a reminder in Dawson James call, John mentioned that the vaccine formulation used in Phase 1 was quote "Okay". The formulation for Phase 11 will be as close to a "commercial" formulation as possible, more stable etc.
My take on that is that the vaccine may well, have even better immune responses if that is even possible, individual patients immune responses may be even more robust.
Note also that in Nov we may find out who the BP partner is as well as the Cancer Institute involved. As tippazz has mentioned previously milestones would most likely be staggered and possible upfront so no further dilution outside of warrants already allocated.
And although 63 mill O/S float is around 36 mill, I would though presume that with new staff and filings they are now close to 70 mill. Still with all the catalysts in place the eventual 100 mill by mid 2016 will still be looked at as within acceptable guidelines. For where we will be at that stage in development.
Barring a R/S in mid 2016 when as John mentioned Quote "all our ducks are in place" for up-list, look at AVXL today 10/11 dollars. Then my 10 dollar prediction is out the window on the low side.
And if a R/S does happen let's say 1 for 4 [leaving 25/30 mill O/S] then within two years we could be in line with KITE and JUNO $30/50.
Just my opinion we will see how things unfold as again within my 18/24 month time frame.
Recurrence to disease once again the pivotal point, hope to hear news on that front soon.
GLTA
BLU
tpizzazz: Overall well presented, one must read between the lines, those of us that are shareholders and in the know realize the potential.
I do wish that management would get more excited about the science [very low key individuals] because to the layman science looks promising, but not as great as it really may be.
2016 does seem to be the catalyst year, does not appear to me that any BP will not be attracted to Tapimmune for many various reasons; once again the two major factors are ‘low cost simple injectable” and low toxicity.
The likes of KITE $62, JUNO $50 seem to have toxicity issues and therefore should be giving us a good look [likely share swap] many others if not all will find the science complementary.
Next 3 to 6 months minimum, this year end start of Phase 11 TNBC and Ovarian, most likely 1st quarter 2016 Her2Nue those two alone are massive.
Numbers quoted alone with TNBC/Ovarian 70,000 total per year not to mention all those already diagnosed, let’s say 70,000 with a $10000 cost per person,$700 million yearly. Cost per individual most likely much higher, low end numbers are still staggering.
These numbers are only North American not worldwide...Herceptin 6 bill alone!
Wondering if FDA will allow commercialization before/entering Phase 3 for TNBC and Ovarian with no approved drugs/vaccines to date?
Remember that they are working/close towards a “commercial” product for initiation of Phase 11, and as per webcast commercial vaccine may be significantly stronger than what we have seen to date, the vaccine combined with Polystart and TAP technology as a complete vaccine [antigens and peptides included] may surpass even the amazing results to date. 16 of 16/ 19/20 etc.
Company is now in hinting on vaccine being able to control Metastasis...the major goal “Holy Grail” for everyone.
Think that BP partners major three Roche/Genentech/Merck just off the top, then there could be second tier likes of KITE, JUNO, ADVAXIS , ACADIA etc, because vaccine may be complimentary to any/all cancers. Not to mention many other diseases that may be controlled that they have not even looked into, after all cancer is the toughest, but vaccine may work in many different areas.
To date no approved T-Cell vaccines, T-Cell make up approximately 75% and apparently can be turned into Killer T cells in the process?
Think that the next 3 to 9 months time frame that John gave will provide many answers, once again would really like to see the recurrence numbers as they pertain to exceeding Herceptin, that is why Roche is very good fit.
Since science seems so good, many others may bid to get science, or sit back and risk allowing competition to hurdle forward.
It does seem that whoever controls Tapimmunes science in the future will be at the forefront without question in Immunology, Tapimmune most likely will not attempt to go it alone expenses would be massive.
John did say that financings have raised approx 10 mill, let’s say they have 6/7 flush cash after expenses incurred last quarter and to year end, with another 8 mill near term, with mentioned .50 cent warrants in the money.
John said burn rate was approx 300,000 per month X12 =3.6 mill per year, although costs will accentuate with additional staff/trials etc, still with grant should be plenty to see them well into Phase 11 on all indications.
2016 will be the defining year with multiple trials up and running, partnership, think that John was right on target by waiting for the up-list until at least two of the trials are into Phase 11, and the partner is on board.
By that time with cash, trials, partner no debt, great science and the big factor “no disease recurrence” or at least better than standard of care now, stock should explode.
Hope that they allow the science to determine the SP, it may take longer but will make for a much stronger company down the road, another R/S to get up-listed in my opinion undermines the strength of the science as well as the company.
Patience12/24 month timeframe [thinking more 12] till we see substantially higher SP and valuation, we are just starting to get validation/noticed 2016 will be Tapimmunes coming out party.
GLTA
BLU
Your welcome: My target[s] of $10 [within 18/24 months] are somewhat conservative compared to valuations in the market/space right now [averaging $15/30/upside 40/50] if the company feels the need to do another R/S then even at 1 for 2 [50 mill O/S] believe that the acquisition/buyout would be more in line with $15/20.
If any R/S occurs [2016] in order to expedite up-list gain access to NASDAQ/NYSE, then could initiate a forward split within 2 years to compensate initial [restructured] investors who have been loyal to company.
If they have the goods a 50 mill float may not be liquid enough for sustainable trading, day in day out of the stock. Then again a low float propels stock much faster/higher, which in turn gives higher S/P/valuation maybe in line with KITE, JUNO [$40/60]
Win-win situation
Phase 11 news [multiple trials] in conjunction with non recurrence surpassing existing products will hopefully allow them to meet/exceed listing requirements without R/S. Hopefully company will allow time and data to propel stock out of OTC status.
Patience, Long term hold but once again think offers will be presented in 2016, stock price will act accordingly. A $3/5 stock bid would not be out of the question at all next year to feel out managements commitment moving forward.
My understanding from Glynn and bringing on board John Bonfiglio, is that they would certainly entertain partner/buyout mid 2016 as costs increase exponentially latter Phase 11.
Fast track and Orphan status news expected TNBC/OVARIAN [possible end 2015, looking for Her2Nue finalize license IND] may solidify any questions BP has on validation of science, 2016 seems a likely timeframe for acquisition/buyout before company gets so much data that market itself takes it into double digits.
Very exciting next 6 to 12 months.
BLU
soulstealer: My hypothesis consists of these factors/details
Company has multiple billion dollar trials commencing within 6/9 months, science is well validated [DOD 13.3 million dollar grant] no to little debt, healthy balance sheet with another 5/10 million cash as stock breaches $1.
Combination science with Tap, Polystart, Folate combined antigen technologies very comprehensive approach to multiple cancers, infectious disease arm another whole market.
Many BP are actively looking for small potentially explosive companies [“compatible” science, with strong patent protection] due to the fact that in 2014 many patents/licences expired leaving a drought in the market.
Although there are many companies tackling various Cancer’s Tapimmune is the “only” one to not have to extract the Killer T-Cells/Helper cells and manipulate them outside the body, then reintroduce them “very, very costly”
Our science unlike any others, “LOW COST, simple injectable, low toxicity, the US health care system cannot sustain overload of expensive Drugs/Vaccines on/coming to market.
Tightening in the immunology space has produced what is already a major demand to seek out acquire small companies before their exposure becomes too well known [ TPIV seems to be on the verge of getting that exposure].
Any news on a more sustained [i.e. extending 24/36 months] lack or recurrence with their vaccines than other Drugs/Vaccines on the market would in my opinion cause a frenzy of bidders.
ARTICLE: The Best Biotech Takeover Targets for 2014
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM • February 10, 2014
This could be the biggest year ever for investing in biotech takeover targets – all due to the patent cliff.
The "patent cliff" refers to the sharp revenue drop a pharmaceutical company faces when the patent on one of its drugs expires. At that point, other drug companies can begin replicating name-brand drugs, cutting into the billions of dollars in revenue that large-cap pharmaceutical companies are used to.
In 2014, nearly $50 billion in pharmaceuticals will be going off patent, according to Bloomberg.
Sanofi (NYSE ADR: SNY), Novartis AG (NYSE ADR: NVS), Roche Holding Ltd. (RHHBY), AstraZeneca PLC (NYSE ADR: AZN), and Eli Lilly & Co. (NYSE: LLY) will all be losing more than $6 billion each in annual revenue this year due to expiring patents.
These large-cap pharmaceutical companies, instead of starting from scratch on a new patent, want an easier and more effective way to replace their lost "cash-cow" revenue. They will look to acquire biotech companies – and their phase II or phase III drugs.
If you were BP would Tapimmune not have peaked your interest, if not before certainly after the DOD validation with a 13.3 million dollar grant for their multiple platforms?
In my opinion even if the science is comparable to others on the market it’s “low cost’ to produce will become the defining factor along with ‘low toxicity’ and simple injectable [already mentioned top of post]
Expect that there is much rustling over at Tapimmune, in regards to BP feeling out their level of resistance to a partnership/buyout; management has on many occasions stated their acceptance to partnering with BP.
With what seems like Tapimmune will exceed Roche’s Herceptin on all fronts [recurrence, toxicity, cost and possible many more markets, if Tapimmunes science which works on boosting the body own immune system naturally and unobtrusively.
There were at least 2 billion dollar plus acquisitions/buyouts exceeding a billion dollars in 2014 with science not as compelling as Tapimmunes, their science [especially the licenses/patents from the mayo] seem to be well protected a must in the Bio tech space.
The risk to Bp whether it comes down to a stock swap or outright buyout would make sense to any BP under 1 billion dollars hence TPIV. With all warrants exercised let’s say 100 mill OS shares $10 dollar share i.e. 1 billion buyout, all Tapimmunes science/technologies are in multiple billion dollar markets [Herceptin 6 billion alone]
BP are looking for synergistic, promising, wide encompassing drugs/vaccines Tapimmune seems to fill all and exceed those and many other criteria, if Tapimmunes vaccine can help the body fight and eradicate Cancer and its effects, what other possible/probable diseases will they be effective on?
So in synopsis do you yourself not “believe” that multiple BP are interested, applying serious DD to Tapimmune?
Hence not “a guess” but an educated statement based on 6 year knowledge of company and Bio sector/BP needs, Tapimmune seems to be a perfect fit to most if not all.
No one wants to be last to the party; the patent expirations have expedited the need/want to acquire new technologies in earlier stages of development than ever before.
We all know that Tapimmune is on the cusp of releasing [3/6/9 months out] what may be the most promising data to date of any company in the immunology sector, the risk to be first to acquire may exceed any need to wait and lose possible market share.
When the best in the business are telling you [Edith Perez. Keith Knutson now the DOD] that their science may be revolutionary, there is no time too soon to be a participant.
If they have not garnered significant interest behind the scenes I would be very surprised.
Hope that gives some clarity.
GLTA
BLU
I have heard a few mention a webcast, I did not see any mention of webcast just a simple meet "n" greet and presentation.
Could anyone show where it states webcast?
Just throwing this scenario out there while we wait for news, how great would it be to get an unsolicited bid for the company ay say minimum $5 early to mid next year [company would refuse of course thereby starting a bidding frenzy, by other companies waiting in the wings]. No worries about waiting for stock to climb, no dilution just wake up and stock is $4 plus and we up list. "SWEET"
A dream...but could also be a real possibility, believe that they are already fielding offers at this point. Mid 2016 with two maybe more Phase 11 trials up and running in multi billion dollar markets "could happen".
GLTA
BLU
The statement
Quote:
the company does not plan to raise the A/S or evoke a R/S.
that comment is misleading to other potential investors, as no one knows, even the company at this point.
In all truth their is always "a possibility" they may choose to do another R/S...look at their past track record in that respect.
Like minded I believe that they will choose not to, and let the science/data speak for itself and the S/P will act accordingly.
Could you make clear the nonsense you are referring too?
And Quote:
At least we know the content is verified and available to purchase.
? What content is available to purchase?
And sorry don't understand
Quote: Those of us with the proper equipment can see the quality and soon, many, many more will as well as the other manufactures come on line.
What manufacturers are coming on line?
Thanks
BLU
Thanks Goines, for those kind words: I also went through the R/S but made out okay in the end. I can’t see the motivation why he would sell [any significant portion] of his shares at such a low price.
Especially since we are on the cusp of initiation and data in regards to 2 possibly 3 Phase 11 trials within 6 month’s as RK has so eloquently mentioned in her posts.
I believe that he has sold some shares here along the way in line with other institutions that got cheap warrants, thus the pressure on the stock to this point.
Having said that would rather have them all sell portions down here then get hit hard when the really good news comes along [eg Phase 11 initiation, recurrence, partnership BP.
I can’t find any other reason that there has been so much pressure on the stock MM manipulation I don’t believe would be that prevalent for this long.
Like others have mentioned Dart seems to hold great companies...and Tapimmune is shaping up to be just that.
Patience I once again we reiterate that I think we are on the verge on making everyone believers, remember that Tapimmunes technology is unprecedented. In the fact that they have a simple low cost, non toxic product, unlike others that have to take cells out manipulate them then reintroduce the cells back into the body...”VERY EXPENSIVE”.
Hillary’s comments may have hurt the Bio tech sector in the short term, but for us down the road it is great because BP must look for technologies that are much more cost effective.
Enjoy the ride believe you have made a great investment choice.
BLU
Saffron76: Not sure how you worded the question...but possibility in regards to their eventual up list.
They need/are strengthening their management [requirement] they also need to be in a stronger cash position which they also have/are working on. Cash from warrants that will be exercised at $1.00 should give settle that requirement, then they need a share price most likely $3 or better.
Would like to see them get to that S/P without another R/S, it looks like right now there are many watching and looking for catalysts like initiation of TNBC Phase 11/Ovarian trial, Fast track and/or Orphan status approval may move us close to $1.
By 2nd quarter of 2016 we should have all catalysts in place knowledge of outcome on the Orphan and Fast track, initiation of at least the TNBC/Ovarian and possibly the Her2Nue breast cancer trial.
Any news such as increased Patent protection, grants, partnerships etc I believe will move us into the $2 to $4 dollar bracket, hence making the up list possible without R/S [mid 2016]
It is exciting right now because if Recurrence to disease passes previous marketed products [eg Herceptin] then that changes the game considerably to the upside, along with any BP collaboration news.
An influx of all those possible scenarios, I think puts us well above $4...but having said that we are on the OTC and will affect us negatively respective to news.
I would like to see them let the science and great news get them to the up list, so have patience saffron it certainly looks like we will get there sooner than later.
There are nothing but positives on the horizon right now and the trading looks like the stock is primed and ready to break out, remember that we are still very, very undervalued at these prices should be $2/3 at this point in regards to others in the space with comparative technology.
I am being very conservative [always am in my investing process] believe that their science is going to be very sought after when the Phase 11 trials are up and running.
In my opinion they have/are already doing DD on possible offers from BP, need to get Polystart into Phase 1 and finish license/IND for the Her2.
Management is doing a great job getting the company into position to up list, better to have a strong company in all aspects then to rush and run into problems 2016/2017.
Hope that helps.
GLTA
BLU
Roche has been my choice also from the outset, Edith Perez and Herceptin match, hard for Glynn to give the farm away now that he has Dart and John to account too. Not to mention how hard he has worked to get to this stage, think a billion [10] would be the starting point.
Don't think that we get anywhere near Phase 111, if science holds out even as Phase 11's start believe that we will be acquired at that point or at least certainly partnered with favorable terms.
Even at this point, the science is so compelling offers are probably circulating and most likely there will be multiple suitors.
Remember that only a year ago as we [those who went through the restructuring] were worried that Tapimmune would not be able to continue as a going concern.
The company has turned around 360, if this was not on the OTC we would be $5/10 minimum already [per others at same stages of tech/trials]
Each time I read about others and their Phase 11 trials being positive in the same space it gives more validation that TPIV's science will hold out and get stronger as Polystart and TAP find their respective places in the vaccine process.
BLU
Thanks tpizzazz24, your contributions are always on point...just another note, for an OTC stock I'm sure most every one would have to admit that Tapimmune has become in the past year a very credible company.
I have always and still think their path forward will be a partnership with a BP or an outright buyout candidate, I believe that there is much going on behind the scenes [positive] that we are not aware.
Put yourselves in the shoes of any BP that is in the immunology space especially cancer, interest must already be peaked and if I was in their shoes would only be waiting for clarification on Orphan and fast track and initiation of both trials.
I would like to see Glynn/John give an update on disease recurrence and stage compared to Herceptin or any others.
If disease recurrence surpasses any/all products on the market this will be highly coveted, the pressure to get their vaccine [early] to market will be overwhelming.
Think of it by mid 2016 Two Phase 11 trials running, the US economy is drowning in healthcare debt. To have a vaccine that performs "as well" or better than existing products should be fast tracked possibly approved much earlier than protocol dictates.
Once again the low cost and lack of toxicity will be a defining factor for any BP, even at this point their vaccine's [data] may be complimentary to most of them in this space filling in gaps or simply strengthening any BP products and lowering their cost to produce products.
Buyout or partial share swap would make sense to many, remember that Tapimmunes TAP technology back in 93 {Wilfred Jefferies inventor] had great success and even back then was touted as, a game changer.
Now in 2015 TAP, POLYSTART, FRa, Antigen presentation etc and we have yet to see how the vaccine performs with all three technology combined.
And we have all but forgotten about the infectious disease arm, and how the vaccine may be manipulated to work in many other areas other than Cancer.
A billion dollar valuation seems quite cheap when Herceptin alone brings in 6/7 billion a year and seems to be inferior to TPIV's vaccines.
Great to have a patent lawyer on board to strengthen/protect technology, and Polystart when up and running seems to hold great promise.
The 13.3 grant should have cleared up much doubt about vaccine working well moving forward.
Commercial product by mid 2016!!!
Thanks to RK for she dedicates more than anyone here, and the collaborative efforts of everyone are appreciated.
Thanks
BLU
When dealing with the FDA, companies must be very, very sensitive about releasing any information that may be interpreted as "front running". Glynn and John know this adhering to strict protocol.
In business as we all know nothing ever gets done on time or for initial cost [always unforeseen expenses and setbacks]
Every ones time frame should be calculated more towards year end, it certainly looks like float is much tighter here, very few sellers.
Many catalyst's moving forward and no foreseeable negatives, even in this market correction, TPIV is rapidly becoming not just a stock to watch but one that needs to be acquired and held.
We all know the story and now the company has undisputed validation, nothing but upside...patience is key here. I believe any news will be big news, remember our valuation is ludicrous and it will be hard for institutions not to start taking positions [even though usually hold to $3/5 entry]
Science, partnerships, no debt positive cash more on the way, partnerships, possible commercial product in Phase 11 [massive] etc.
In two years time don't be surprised if Tapimmune becomes a market darling look for partnership with BP in 2016.
Need company to give color on recurrence to disease that is a defining factor, each passing month if science holds [recurrence] helps not hinders us.
It is an exciting stock to be in right now...don't let doubt set in, Tapimmune is the real deal, time is our friend. When the two Phase two's are up and running [1st half of 2016] we will have BP's attention and support.
GLTA
BLU
Clarification: A long term investor in Tapimmune, Tapimmune "the Company" has "NEVER" to my extensive knowledge, inflated either their finacials or embellished facts or press in order to garner a more substantial stock price.
Glynn is actually renowned as being almost stoic in his overall presentation of news, and strictly adheres to SEC guidelines in all aspects of the Company.
Management is well versed on SEC protocols, and in my opinion the company is well staged for the next tier [initiation of Phase 11's]
GLTA
BLU
saffron76: Chaikin Money Flow
Introduction
Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.
Calculation
There are four steps to calculating Chaikin Money Flow (CMF). The example below is based on 20-periods. First, calculate the Money Flow Multiplier for each period. Second, multiply this value by the period's volume to find Money Flow Volume. Third, sum Money Flow Volume for the 20 periods and divide by the 20 period sum of volume.
1. Money Flow Multiplier = [(Close - Low) - (High - Close)] /(High - Low)
2. Money Flow Volume = Money Flow Multiplier x Volume for the Period
3. 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume
Each period's Money Flow Volume depends on the Money Flow Multiplier. This multiplier is positive when the close is in the upper a half of the period's high-low range and negative when the close is in the lower half. The multiplier equals 1 when the close equals the high and -1 when the close equals the low. In this way the multiplier adjusts the amount of volume that ends up in Money Flow Volume. Volume is in effect reduced unless the Money Flow Multiplier is at its extremes (+1 or -1).
Chart 1 - Chaikin Money Flow
The table above shows some examples using daily data for Research in Motion (RIMM). Notice how the multiplier was near +1 on 5-Jan when the stock closed near its high. The multiplier dipped to -.97 on 18-Jan when the stock closed near its low. The multiplier finished near zero (-.07) when the stock closed near the mid point of its high-low range on 29-Dec. Click here for a calculation example of Chaikin Money Flow in an Excel Spreadsheet.
Interpretation
Chaikin Money Flow (CMF) is an oscillator that fluctuates between -1 and +1. Rarely, if ever, will the indicator reach these extremes. It would take 20 consecutive closes on the high (low) for 20-day Chaikin Money Flow to reach +1 (-1). Typically, this oscillator fluctuates between -0.50 and +0.50 with zero as the centerline.
Chart 2 - Chaikin Money Flow
Chaikin Money Flow measures buying and selling pressure for a given period of time. A move into positive territory indicates buying pressure, while a move into negative territory indicates selling pressure. Chartists can use the absolute value of Chaikin Money Flow to confirm or question the price action of the underlying. Positive CMF would confirm an uptrend, but negative CMF would call into question the strength behind an uptrend. The reverse holds true for downtrends.
Buying/Selling Pressure
Chaikin Money Flow can be used to define a general buying or selling bias simply with positive or negative values. The indicator oscillates above/below the zero line. Generally, buying pressure is stronger when the indicator is positive and selling pressure is stronger when the indicator is negative.
While this zero line cross seems simple enough, the reality is much choppier. Chaikin Money Flow sometimes only briefly crosses the zero line with a move that turns the indicator barely positive or negative. There is no follow through and this zero line cross ends up becoming a whipsaw (bad signal). Chartists can filter these signals with buffers by setting the bullish threshold a little above zero (+0.05) and the bearish threshold a little below zero (-0.05). These thresholds will not entirely eliminate bad signals, but can help reduce whipsaws and filter out weaker signals.
Chart 2 - Chaikin Money Flow
The chart above shows Freeport McMoran (FCX) with 20-day Chaikin Money Flow in the indicator window. There were at least 10 crosses of the zero line between February and December 2010. Adding a small buffer greatly reduced the number of bullish and bearish signals. A move above +0.05 was considered bullish, while a move below -0.05 was considered bearish. There were only three signals. While these signals will come a little later, it may be worth it to reduce whipsaw.
Poor Bloke: Totally get it, Kudo's for you for taking care of your family before the market, I know from experience how hard it is to not want to invest what little cash you may have.
Thinking that the investment will recover/make the money you may need...that is a quality individual. For many times it may go the other way, it is also much harder to deny those urges as we get older, hoping to make money faster.
I myself took on 6 children and now 25 grandchildren when my Aunt passed away suddenly, the gift of having the big and little ones in my life far outweigh the expense [more the little ones...LOL.
There is always money to be allocated 24/7...but I believe that a true mark of a man/Woman, forgoes for themselves to do what is right for those that cannot.
You will be rewarded in time this life or the next!
There is no greater gift then giving of yourself,when you yourself have little to give.
Best of luck in this investment...I believe that you have made a wise choice and will be rewarded in kind with Tapimmune.
GLTY
BLU
Poor bloke...there is some merit to what he says.
Although many of us would like one more kick at the can [so to speak] one more time to get a few more cheap shares, I think it is at best a 50/50 proposition at this point.
True that the news did not immediately escalate the S/P, if you noticed on Friday the trading seemed to be much more concentrated with many block trades, that in my opinion were more inclined to be funds and/or brokers depositing shares in clients accounts [many 15000/20000 blocks].
The grant most likely tilted the scales in the eyes of many investors as to whether the companies science would stand up to fierce scrutiny, I believe the DoD grant has in many relieved those concerns.
Think of it as if you were on the sidelines, there has been nothing but positives with the company over the past year, successful restructuring, great collaborations by some of the most respected minds in the industry [Perez, Knutson, Dart] enough cash to enter and after the $1 warrants are exercised to complete another Phase 11 trial.
Any educated investor knows that a Bio tech play [phase 1 through 3] is a minimum of 7 years and most 11 years. Many companies never get through Phase 1, we have accomplished that and the validation with the grant pretty much ensures I would think FDA approval of both Orphan Status and Fast Track, in regards to not just the Folate Receptor [TNBC/Ovarian], but also the Her2Nue Breast Cancer trial.
The manipulators can only sell/drive down the stock for so long before the news/science/potential of the company outweighs those risks...I think we are very close to that realization.
So I would think any savvy investor has had a few days to digest the information and a decision must be made, we all know that there are/were many funds/brokers/investors waiting for some kind of validation outside of the company...that has now occurred.
There are absolutely no fundamental negatives with the company at this point, if I did not already have a large position and was on the sidelines/fence that news would have made me a buyer end of last week. As it is if this happens to drop once more [.50 or under] I will be buying again, I have been accumulating more, anything under .50.
That may not be the lowest it will go but in my opinion anything .50 or less is a definite steal, we never get the low you simply have to find a price that you can live with not try to get the lowest price but simply average as you go along.
The news to me was outstanding, and I cannot wait for 2016 to begin I would not be adverse to one more drop to get my final shares, having said that watching the buying Friday did convince me that they will be a whole new wave of buying.
It will just be a battle of the wills, manipulators or buyers either way I believe that we are much closer to this moving significantly up than down by year end...give me one more opportunity and I will scoop up more, then enjoy the ride up.
Be honest with yourselves has anyone really seen a better story/science unfolding right before our eyes, I have been an investor over 30 years and Tapimmune is on the cusp of being the best trade I may ever make.
Each month that progresses with non recurrence in patients [although we are looking at delays as hurtful] makes the science/company that more sound.
Early 2016 if they can initiate minimum 2 Phase 11 trials, with another 10 million cash, improved board and up-list can you imagine the Funds/Brokers that will/are waiting to buy the stock it may be the perfect storm.
Up or down from here?
Only manipulators will be sellers at this stage...if they prevail then us/we will be the winners as we get one last chance to get cheap shares...and I do believe the very last chance.
GLTA
BLU
tpizzazz24...lol it's Keith Knutson not Kurt.
Undtrdr...thanks very much for the PM and the link, welcome fellow Canadian I am in the Kawartha's [Bobcaygeon]
For the $130 are the quotes real time, and do they have multiple Bid and Ask [ie Bid .60, .595, .59, .585 etc] and do they show daily previous trades?
Is the trial worth taking?
Thanks BLU
Thanks bud was looking for more in depth than just first round of Bid and Ask, like next 10 lower in the Que...but I realize that it is too much to ask.
Got in touch with TD Canada and they cant help me with TD Ameritrade, plan to start spending winters in Nokomis Florida next year or two. May be able to set up an Ameritrade account ahead of time.
Thanks again
BLU
Mathew...am with TD Canada and it does not support OTC stocks even on level two or so they have told me, does ETRADE have otc level two?
Anyone else on ihub service?
Thanks
BLU
Question: Does anyone have level 11 on ihub, is it real time, .15 minute delay, shows all prior trades bid and ask and is it worth the $29 bucks?
Thanks in advance.
BLU
Thanks, it has been a very long road [for me at least] I just want to say thank you to all of you for your kind words along the way.
I have never doubted the technology as you all well know, I am so happy that such a great bunch of people as the ones on this board are going to share in the future rewards.
Can you just imagine if they time the up-list to Nasdaq with having two Phase 11 trials up and running, can you just imagine the fury of buyers that are/were not able to participate because of 3/5 dollar rule.
My prediction of $10 minimum may very well come to fruition.
GLTA
BLU
Lets hope they use their cash to expedite, the her2Nue phase 11 trial, by 1st quarter of 2016 it would be great to have minimum 2 phase 11 trials in Multi Billion dollar markets.
Now the FDA approval process for "fast tracking" the Folate receptor may be a much simpler and expedited process.
Tapimmune is really beginning to get the validation they deserve.
2016 looks like a very good year.
GLTA
BLU
Not sure...but they sure have been hinting more and more in the past two conferences/webcasts.
Would personally like to see them wait till all Phase 11's are up and running, give them much more leverage...but I am sure the BP is thinking just the opposite.
I don't think that it will be as far away as 2016, think by year end, either way as I mentioned they have cash for trials, hope they don't give up too much, terms should be in their favour.
BLU
Money should not be an issue, after the exercise of the recent warrants, I think they should have in excess of 6 million [unless they have already allocated/spent some]
Enough cash above $1.00 to see them through all Phase 11 trials alone [without partner]
Then as company has alluded too on numerous occasions, it looks like a collaboration/partnership is in the near future. Then there is the possibility of funding from the grant they have applied for.
The wed conference should be quite positive, in regards to Phase 11 start, and the collaboration [which if comes to fruition most likely would have milestone payments] or maybe cash upfront or funding when needed. Depending on the structure, they should be in a power position with the negotiations, glad we have Bonfiglio to negotiate the terms.
They have really executed their plan very well, am really interested in who the collaboration is with [Merck. Roche]?
BLU
Sugar: There was only one question, no relevance.
On the Sept 16 next Wed, there will be a Q/A for everyone.
Don't believe today's has a webcast, next week will give good color and more clarity hopefully.
GLTA
BLU
You couldn't be more wrong, they are on the edge of Phase 11 in multiple indications .32 is/was a ridiculous SP/valuation. With the catalyst's they have in place next 4 month's comparative stocks are minimum .75 +.
The OTC listing is the only reason this stock has the SP/valuation it has, pure manipulation, the science has only gotten more credible.
Have non of you done your DD on the "science"?
BLU
No...the science does!
Not only that "Resume" some of us were buyers, "My tears" are tears of joy, if is happens to retract "don't think so at this point in time" with Phase 11 inevitable next 30/90 days.
I will be a buyer again, right now my recent buys seem substantially on the upside.
BLU
Dude...really? It's called exposure, how else are OTC stocks going to get it.
Just because Tapimmune has not had the luxury of being touted by the likes of giant houses like KITE and JUNO has, does not take anything away from the "science" which is all journal peer reviewed by the likes of Edith Perez, Keith Knutson and others.
The science will prove out despite penny manipulators, really think that Edith Perez would make claims such as the video in early 2015...without a substantial validation process internally.
Yes we are well warned once again.
See you in 2016 or sooner.
BLU
You obviously have no clue about the company, science or management, most of us here are for the long term and "believe" in the science and what it may accomplish.
Who cares about .10 or .20 cents here or there...if you had done your DD you would know that TPIV may be on the cusp or something truly eventful. It has the very real possibility of being a high flier like KITE and JUNO, not to mention if this conference call gives color on initiation of Phase 11 in Ovarian and TNBC.
Possible partnership, Polystart, grant etc, ect no offence but do you really think that JBEM or whoever he/they are will/can control Tapimmunes eventual rise?
The science will prove out...but thanks we are well warned "LOL"
GLTY
BLU
You obviously have no clue about the company, science or management, most of us here are for the long term and "believe" in the science and what it may accomplish.
Who cares about .10 or .20 cents here or there...if you had done your DD you would know that TPIV may be on the cusp or something truly eventful. It has the very real possibility of being a high flier like KITE and JUNO, not to mention if this conference call gives color on initiation of Phase 11 in Ovarian and TNBC.
Possible partnership, Polystart, grant etc, ect no offence but do you really think that JBEM or whoever he/they are will/can control Tapimmunes eventual rise?
The science will prove out...but thanks we are well warned "LOL"
GLTY
BLU
"scottsmith" Appreciate you weighing in on my behalf, you are correct, I'm sure tippazz was just trying to make the point that I was not concerned at the steep decline in share price.
Thanks...I was not going to respond, as I usually try not to post on my personal holdings, but wish to clear up this point.
I participated in a bridge financing and at that time approx. 90% of my holdings were at .14, since then I have made purchases ranging from .20 to .48 cents.
I bought my shares for a two year window and am not concerned at all, my average is approx .31 at this point in time.
Although the R/S hurt me I was left with 10,000 shares
[from 1 mill] and was able to sell into the $7 dollar run up to recoup most of the R/S losses.
My reasoning for not selling into the run up, is purely Tax related, as here in Canada we have a 50% capital gain tax, and I have enough assets that I wouldn't give the tax man the satisfaction.
I have made small purchases on some of the waves of decline, and have holdings of TPIV at 200,000 shares. I realize that no one is really interested in my holdings this is just clarification.
So I am approaching even, that's with the restructuring behind us as we speak.
At this moment I am not a buyer, but have bought in the past two weeks, and if world markets dictate I will be a buyer again sub .30. I do believe that these prices are a steal, despite what others may say about the warrant overhang.
I am confident that the science will prevail, so am just happy to sit back and let my shares work for me over the next couple of years.
I do appreciate the level of sophisticated investors on this board, and look forward to us all being vindicated as Tapimmune's science becomes fully embraced.
As someone once said...the best is yet to come.
GLTA
BLU
Fundamentals have gotten substantially stronger in the past year!
This post is for the more novice traders, as veteran investors have been here many times before.
The Bio tech sector is highly volatile, and the average timeframe to bringing a drug to market is over 7 years, Tapimmune has a vaccine that defies what most of the industry has accepted.
A simple injection, low cost, low toxicity, the rest of the industry goes to length to harvest the cells, manipulate them then re-introduce them into the body [cost enormous].
There are many types of investors, but the two main are those that frequently trade a given stock and those that buy and hold, you should know who you are, and what is your maximum risk tolerance. The greatest investors in the world buy when others do not have the guts to stand by their convictions. Investing 101 a proven theory, dictates that if the fundamentals of a company do not substantially deviate to the downside [or get stronger TPIV's case] then to dollar cost averaging is an intelligent way to increase ones position.
Tapimmune is on the cusp of what many industry leaders believe may be one of the most important vaccine/drug findings in recent history. It has proven to be safe, and provide "ROBUST" immune responses in over 90% of patients to date, as each month passes we get into unchartered territory in regards to disease recurrence.
If you are not a trader, but an investor than I cannot think of a better play right now than Tapimmune, get your position and then forget it. If they have what they say it will change all our lives, if they don't it will be like any other stock you could invest in and lose you money.
Most of us are in at lower prices than we see here today, so what is the worry, for those that are in at higher levels do not let the actions of those that control the market [not Tapimmune's science] dictate your destiny. There is a much higher probability that TPIV will be successful, than for it to fail at this point.
By year end the story will become substantially more accepted, in this world there is always someone more powerful, more money and more scrupulous than you or I.
That seems to be what is at play here.
Stand by your convictions, or sell out to those who's agenda has nothing to do with "Cancer" or Tapimmunes "science", I believe TPIV's vindication is much closer that the market dictates.
I still see no negatives [other than the SP] and many, many catalyst's in the near term [four months max] If they do indeed have a vaccine for many cancers, or the potential to strengthen those vaccines/drugs already to market. It will be a win/win scenario, a buyout or a much higher SP in the future.
Decide who you are and act accordingly...once again two years from now at the very least 100,000's of lives may be saved or prolonged due to Tapimmune's science.
With all the data too date...I am willing to accept that risk R you?
GLTA
BLU